64x Bio GTM brain

64x Bio licenses engineered cell lines and production systems to developers and manufacturers of advanced therapies.

category

Advanced therapy manufacturing platforms

market profile

  • text: Viral vector yields and manufacturing capacity can constrain the progress and economics of gene therapies.
  • text: The platform now spans AAV and lentiviral production, with biologics planned.

personas

  • title: VP, Technical Operations or CMC at a gene therapy developer
    pains:
    • Low vector yield makes clinical or commercial supply expensive and difficult to scale.
    • A process must work across the program's payload and intended manufacturing scale.
  • title: Head of process development at a cell and gene therapy CDMO
    pains:
    • Existing production cell lines limit output and capacity across client programs.
    • Introducing new cell lines requires evidence and a workable technology transfer.
  • title: Head of cell therapy manufacturing
    pains:
    • Lentiviral vector supply can constrain CAR-T manufacturing.
    • The team needs a scalable production system for its specific program.

icp

  • text: Biopharma and biotech companies developing AAV gene therapies or CAR-T programs, particularly those advancing toward larger manufacturing runs.
  • text: CDMOs with advanced therapy manufacturing capacity that can adopt or license production cell lines for multiple programs.

message pillars

  • text: Engineer yield using high-throughput screening and computation.
  • text: Support AAV programs across diverse configurations and scales.
  • text: Offer a dedicated lentiviral system for CAR-T programs.

objections

  • objection: Will a new cell line work with our payload and process?
    response: Request program-specific data and a technical assessment of compatibility and transfer before committing.
  • objection: We already have a CDMO and production process.
    response: Evaluate the cell line as a potential input to the existing process with the CDMO, including comparability and transfer costs.
  • objection: Can the economics justify changing platforms?
    response: Compare expected yield and capacity against licensing, development and validation costs on a defined program.

competitors

  • name: Asimov
    website: https://www.asimov.com/
    why: Offers engineered AAV and lentiviral producer cell lines and development services.
  • name: Viralgen
    website: https://viralgen.com/process/aava?hsCtaAttrib=284166312125
    why: Offers an AAV manufacturing platform using a proprietary cell line, an alternative route to scalable production.

influencers

  • name: Lexi Rovner
    url: https://64xbio.com/company
    why: Co-founder and CEO speaking publicly about cell line engineering and therapy manufacturing.

keywords

  • AAV producer cell line
  • viral vector manufacturing yield
  • lentiviral vector production
  • gene therapy manufacturing scale up
  • CAR-T vector supply
  • cell line engineering

voice

  • Scientific and technically specific
  • Mission-driven about access to advanced medicines
  • Confident and focused on manufacturing scale

signals

  • text: A gene therapy program is moving from research toward clinical or commercial vector production.
  • text: A CDMO is expanding AAV or lentiviral capacity or seeking a higher-yield platform.

pricing

model: unknown

motion

sales_led

channels

  • LinkedIn
  • industry events
  • partnerships
  • press

confidence

medium

Founders

  • name: Lexi Rovner
    title: Founder/CEO
    role: CEO
    bio: Lexi Rovner, PhD is the CEO & co-founder of 64x Bio, a spinout of Harvard Medical School and the Wyss Institute. Lexi completed her PhD at Yale University and her postdoctoral work in George Church’s lab at Harvard Medical School, where she co-founded the company alongside George, Pam Silver, Jeff Way, and David Thompson. Lexi is a Y Combinator alum, a 2022 Endpoints 20 under 40 Next-Generation Biotech Leader, and a 2022 Bloomberg New Economy Catalyst Awardee.

Back to YC companies